Evidence map›Paper›PMID 24531649›Full record

ArticleInternational journal of nanomedicine2014

Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells.

Maryam Tahmasebi Mirgani, Benedetta Isacchi, Majid Sadeghizadeh, Fabio Marra, Anna Rita Bilia, Seyed Javad Mowla, Farhood Najafi, Esmael Babaei

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 134 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Upregulation ofIndian journal of clinical biochemistry : IJCB · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. The Involvement of Canonical NFκB Pathway in Megakaryocyte Differentiation Induction by Nanocurcumin.International journal of hematology-oncology and stem cell research · 2023
    Article
  15. Investigation of Curcumin-Loaded OA400 Nanoparticle's Effect on the Expression ofIranian journal of pharmaceutical research : IJPR · 2022
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Maryam Tahmasebi MirganiDepartment of Genetics, Tarbiat Modares University, Tehran, Iran.
Benedetta IsacchiDepartment of Chemistry, University of Florence, Sesto Fiorentino, Italy.
Majid SadeghizadehDepartment of Genetics, Tarbiat Modares University, Tehran, Iran.
Fabio MarraDepartment of Experimental and Clinical Medicine, University of Florence, Italy.
Anna Rita BiliaDepartment of Chemistry, University of Florence, Sesto Fiorentino, Italy.
Seyed Javad MowlaDepartment of Genetics, Tarbiat Modares University, Tehran, Iran.
Farhood NajafiDepartment of Resin and Additives, Institute for Color Science and Technology, Tehran, Iran.
Esmael BabaeiDepartment of Biology, University of Tabriz, Tabriz, Iran.
Tarbiat Modares University · IRUniversity of Florence · ITInstitute for Color Science and Technology · IRUniversity of Tabriz · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is an invasive tumor of the central nervous system. Tumor recurrence resulting from ineffective current treatments, mainly due to the blood-brain barrier, highlights the need for innovative therapeutic alternatives. The recent availability of nanotechnology represents a novel targeted strategy in cancer therapy. Natural products have received considerable attention for cancer therapy because of general lower side effects. Curcumin is a new candidate for anticancer treatment, but its low bioavailability and water solubility represent the main disadvantages of its use. Here, curcumin was efficiently encapsulated in a nontoxic nanocarrier, termed dendrosome, to overcome these problems. Dendrosomal curcumin was prepared as 142 nm spherical structures with constant physical and chemical stability. The inhibitory role of dendrosomal curcumin on the proliferation of U87MG cells, a cellular model of glioblastoma, was evaluated by considering master genes of pluripotency and regulatory miRNA (microribonucleic acid). Methylthiazol tetrazolium assay and flow cytometry were used to detect the antiproliferative effects of dendrosomal curcumin. Annexin-V-FLUOS and caspase assay were used to quantify apoptosis. Real-time polymerase chain reaction was used to analyze the expression of OCT4 (octamer binding protein 4) gene variants (OCT4A, OCT4B, and OCT4B1), SOX-2 (SRY [sex determining region Y]-box 2), Nanog, and miR-145. Dendrosomal curcumin efficiently suppresses U87MG cells growth with no cytotoxicity related to dendrosome. Additionally, the accumulation of cells in the SubG1 phase was observed in a time- and dose-dependent manner as well as higher rates of apoptosis after dendrosomal curcumin treatment. Conversely, nonneoplastic cells were not affected by this formulation. Dendrosomal curcumin significantly decreased the relative expression of OCT4A, OCT4B1, SOX-2, and Nanog along with noticeable overexpression of miR-145 as the upstream regulator. This suggests that dendrosomal curcumin reduces the proliferation of U87MG cells through the downregulation of OCT4 (octamer binding protein 4) variants and SOX-2 (SRY [sex determining region Y]-box 2) in an miR-145-dependent manner.

Indexed as

Antineoplastic Agents, PhytogenicApoptosisCaspasesCell CycleCell DeathCell Line, TumorChemistry, PharmaceuticalCurcuminDown-RegulationDrug CarriersDrug StabilityGlioblastomaHomeodomain ProteinsHumansMicroRNAsMolecular Targeted TherapyAntineoplastic Agents, PhytogenicCaspasesCurcuminDrug CarriersHomeodomain ProteinsMicroRNAsMIRN145 microRNA, humanNanocapsulesNanog Homeobox ProteinNANOG protein, humanOctamer Transcription Factor-3POU5F1 protein, humanSOX2 protein, humanSOXB1 Transcription FactorsTranscription Factorsdendrosomal curcuminglioblastomamiRNApluripotency gene

Identifiers

PMID24531649
PMCPMC3894954
OpenAlexW2154354520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.